Zhang Feng, Li Danni, Li Yanshuang, Li Haixia, Sun Jinbo, Li Xianfeng, Li Xiaohong
Department of Neurology, Jinan Central Hospital Affiliated to Shandong University, Jinan, 250013, China.
Tumour Biol. 2014 Jan;35(1):747-51. doi: 10.1007/s13277-013-1101-8. Epub 2013 Sep 18.
Many studies have investigated on the association between TP53 Arg72Pro polymorphism and risk of glioma, but the impact of TP53 Arg72Pro polymorphism on glioma risk is unclear owing to the obvious inconsistence among those studies. To shed light on these inconclusive findings and get a quantitative assessment of the association between the TP53 Arg72Pro polymorphism and risk of glioma, we conducted a meta-analysis of eligible studies. We searched PubMed and Embase databases for studies investigating on the association between the TP53 Arg72Pro polymorphism and risk of glioma. The pooled odds ratios (OR) with their 95% confidence intervals (95% CI) was calculated to assess the association between the TP53 Arg72Pro polymorphism and risk of glioma. A total of 12 studies were finally included into the meta-analysis. Meta-analysis of the 12 studies showed that TP53 Arg72Pro polymorphism was not associated with the risk of glioma (OR(Pro vs. Arg) = 1.07, 95% CI 0.93∼1.22; OR(ProPro vs. ArgArg) = 1.02, 95% CI 0.85∼1.22; OR(ProPro/ArgPro vs. ArgArg )= 1.06, 95% CI 0.85∼1.34; and OR(ProPro vs. ArgArg/ArgPro) = 1.07, 95% CI 0.91∼1.27). Subgroup analyses by ethnicity further identified that TP53 Arg72Pro polymorphism was not associated with the risk of glioma in Caucasians. However, there was a mild association between the TP53 Arg72Pro polymorphism and risk of glioma in Asians (OR(ProPro vs. ArgArg/ArgPro) = 1.42, 95% CI 1.00∼2.02). Thus, there is limited evidence for the association between the TP53 Arg72Pro polymorphism and risk of glioma, and more studies are needed to provide a more comprehensive assessment of the association in Asians.
许多研究探讨了TP53基因Arg72Pro多态性与胶质瘤风险之间的关联，但由于这些研究结果明显不一致，TP53基因Arg72Pro多态性对胶质瘤风险的影响尚不清楚。为了阐明这些不确定的研究结果，并对TP53基因Arg72Pro多态性与胶质瘤风险之间的关联进行定量评估，我们对符合条件的研究进行了荟萃分析。我们在PubMed和Embase数据库中检索了关于TP53基因Arg72Pro多态性与胶质瘤风险关联的研究。计算合并比值比（OR）及其95%置信区间（95%CI），以评估TP53基因Arg72Pro多态性与胶质瘤风险之间的关联。最终共有12项研究纳入荟萃分析。对这12项研究的荟萃分析表明，TP53基因Arg72Pro多态性与胶质瘤风险无关（OR（Pro vs. Arg）=1.07，95%CI 0.93～1.22；OR（ProPro vs. ArgArg）=1.02，95%CI 0.85～1.22；OR（ProPro/ArgPro vs. ArgArg）=1.06，95%CI 0.85～1.34；OR（ProPro vs. ArgArg/ArgPro）=1.07，95%CI 由种族进行的亚组分析进一步确定，TP53基因Arg72Pro多态性与白种人患胶质瘤的风险无关。然而，在亚洲人中，TP53基因Arg72Pro多态性与胶质瘤风险之间存在轻度关联（OR（ProPro vs. ArgArg/ArgPro）=1.42，95%CI 1.00～2.02）。因此，TP53基因Arg72Pro多态性与胶质瘤风险之间关联的证据有限，需要更多研究以对亚洲人群中的这种关联进行更全面的评估。
